Obesity injection causes major weight loss in clinical trial

A new once-monthly injection for obesity, maridebart cafraglutide, resulted in significant weight loss, up to 16%, in a recent clinical trial. This offers a promising new treatment option for individuals struggling with obesity. The Phase 2 trial involved adults with and without diabetes, showing weight reduction and improved blood sugar control. The drug, administered every four weeks, demonstrated an acceptable safety profile, with gastrointestinal side effects being the most common. The findings support further study in Phase 3 trials, potentially offering a more convenient and effective treatment for obesity. The study also highlighted the importance of dose escalation to manage side effects.